pp2a-α

DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.

Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride 可能会引起致敏作用。 Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride 促进 HepG2 （IC50= 62μM）和SK-Hep1（IC50= 151μM）细胞凋亡且对蛋白磷酸酶2A具有抑制作用。

D-erythro-Sphingosine (trans-4-Sphingenine) 是一种非常有效的p32激酶活化剂，EC50为 8 μM。它也是一种PP2A 激活剂，抑制蛋白激酶 C (PKC)。

Okadaic acid 是一种强效的聚醚海洋毒素，在海洋软体动物的消化腺中积聚。Okadaic acid 是一种具有高效性和选择性的蛋白质磷酸酶 (PP) 抑制剂，抑制 PP1、PP2A 、PP3 、PP4 和 PP5 。Okadaic acid 激活人 HepaRG 细胞中的 Wnt β-catenin 信号传导。

N-Stearoylsphingosine (Cer(d18:1 18:0)) 是一种广泛存在真核生物体内的酰胺类化合物，通过干扰PP2A与PP2A抑制剂2的结合来增强蛋白质磷酸酶2A(PP2A)活性，导致Akt去磷酸化。N-Stearoylsphingosine 可用于研究前列腺癌。

LB100 (LB-100) 是一种水溶性蛋白磷酸酶 2A(PP2A) 抑制剂。

PP2A Cancerous-IN-1 是强效的 CIP2A(Cancerous inhibitor of PP2A) 和 p-Akt 抑制剂，表现出强大的抗增殖作用。

Endothall 是蛋白磷酸酶 2A (PP2A) 抑制剂，能够抑制PP2A (IC50: 90 nM) 和 PP1 (IC50: 5 uM) 。它可作为除草剂，在癌症化疗过程中也能够发挥作用。

Calyculin A ((-)-Calyculin A) 是日本海洋海绵 CDiscodermia calyxC 中的毒性物质，是一种具有选择性和高效性的蛋白磷酸酶 1 (PP1) 和蛋白磷酸酶 2A (PP2A) 抑制剂， 诱导冷冻保存牛精子的过度激活，抑制人淋巴细胞中辐射诱导的 gammaH2AX DNA 修复病灶的消失。

(Rac)-LB-100 是-LB-100 的外消旋体。LB-100 是一种新型蛋白磷酸酶 2A (PP2A) 抑制剂，可使恶性脑膜瘤细胞对放射治疗效果敏感。

MP07-66 是 FTY720 的一种类似物，没有免疫抑制作用。MP07-66通过破坏 SET-PP2A 复合物导致PP2A 重新激活。MP07-66在慢性淋巴细胞白血病中显示出良好的抗肿瘤作用。

Tautomycin is a potent and specific protein phosphatases 1 and 2A inhibitor (Kiapp of 0.16 nM and 0.4 nM for PP1 and PP2A, respectively), and is an antifungal antibiotic isolated from the bacterium Streptomyces verticillatus.

TD52 是 PP2A (CIP2A) 癌性抑制剂的口服活性抑制剂。 TD52 是厄洛替尼衍生物，通过干扰 Elk1 与 CIP2A 启动子的结合间接降低了 CIP2A。

Okadaic acid ammonium salt, a marine toxin, serves as an inhibitor of protein phosphatases (PP), displaying a higher affinity for PP2A (IC 50 =0.1-0.3 nM) alongside inhibitory effects on PP1 (IC 50 =15-50 nM), PP3 (IC 50 =3.7-4 nM), PP4 (IC 50 =0.1 nM), and PP5 (IC 50 =3.5 nM), but does not affect PP2C. By inhibiting PPs, this compound promotes protein phosphorylation and acts as a tumor promoter. Additionally, it is involved in inducing tau phosphorylation.

PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.

NPA101.3 is a a Second-Generation RET VEGFR2 Inhibitor. It is a potential clinical candidate for RET-driven cancers.

TPP2a is a mitochondrial thioredoxin reductase (TrxR) inhibitor.

Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1 p38 MAPK pathway.